Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Current Liabilities: 2023-2025

Historic Total Current Liabilities for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $30.5 million.

  • CG Oncology's Total Current Liabilities rose 95.32% to $30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.5 million, marking a year-over-year increase of 95.32%. This contributed to the annual value of $21.4 million for FY2024, which is 49.91% up from last year.
  • As of Q3 2025, CG Oncology's Total Current Liabilities stood at $30.5 million, which was up 0.48% from $30.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Total Current Liabilities registered a high of $30.5 million during Q3 2025, and its lowest value of $10.0 million during Q1 2024.
  • For the 3-year period, CG Oncology's Total Current Liabilities averaged around $19.6 million, with its median value being $18.5 million (2024).
  • Data for CG Oncology's Total Current Liabilities shows a peak YoY surged of 156.31% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows CG Oncology's Total Current Liabilities stood at $14.3 million in 2023, then skyrocketed by 49.91% to $21.4 million in 2024, then surged by 95.32% to $30.5 million in 2025.
  • Its Total Current Liabilities was $30.5 million in Q3 2025, compared to $30.4 million in Q2 2025 and $22.6 million in Q1 2025.